Theriva Biologics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Theriva Biologics, Inc. (TOVX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures of 0 shares for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-10.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod · last filed 2020-11-10
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2020-09-30 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2020-06-30 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2020-03-31 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for the quarter ending 2019-09-30 was 0.00 shares.
- Theriva Biologics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, net of forfeitures for fiscal 2011 was 557.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures 12 month |
|---|---|---|---|---|
| 2020-09-30 | 0.00 shares 10-Q · filed 2020-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-10 | 0.00 shares 10-Q · filed 2020-11-10 | |
| 2020-06-30 | 0.00 shares 10-Q · filed 2020-08-06 | 0.00 shares 10-Q · filed 2020-08-06 | ||
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-05 | |||
| 2019-09-30 | 0.00 shares 10-Q · filed 2020-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-10 | 0.00 shares 10-Q · filed 2020-11-10 | |
| 2019-06-30 | 0.00 shares 10-Q · filed 2020-08-06 | 0.00 shares 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | 0.00 shares 10-Q · filed 2020-05-05 | |||
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-04 | 0.00 shares 10-Q · filed 2019-11-04 | ||
| 2013-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2013-11-14 | 117.50K shares 10-Q · filed 2013-11-14 | 352.50K shares derived: sum of 4 quarters · filed 2013-11-14 |
| 2013-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | 117.50K shares 10-Q · filed 2013-08-14 | 352.50K shares derived: sum of 3 quarters · filed 2013-11-14 | 642.50K shares derived: sum of 4 quarters · filed 2013-11-14 |
| 2013-03-31 | 117.50K shares 10-Q · filed 2013-05-15 | 352.50K shares derived: sum of 2 quarters · filed 2013-11-14 | 642.50K shares derived: sum of 3 quarters · filed 2013-11-14 | |
| 2012-12-31 | 235.00K shares derived: 10-Q 12 month − 10-Q 9 month · filed 2013-11-14 | 525.00K shares derived: sum of 2 quarters · filed 2013-11-14 | 2.08M shares 10-Q · filed 2013-11-14 | |
| 2012-09-30 | 290.00K shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2012-11-14 | 1.84M shares 10-Q · filed 2012-11-14 | ||
| 2012-06-30 | 1.55M shares 10-Q/A · filed 2012-09-11 | |||
| 2011-12-31 | 557.00K shares 10-K · filed 2013-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |